Novozymatic
ActiveThe computed 12-month bankruptcy probability of Novozymatic is 2.5% (moderate). The 2025 annual accounts show negative equity (€-352k) and a net result of €-98k. Equity is shrinking by ~63.8% per year across the filed fiscal years. Its solvency ranks better than 13% of 60 sector peers (fiscal year 2025). The company has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals.
Checked score
Score 2025
34
/ 100
Weak
The score weighs solvency, liquidity and profitability. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability0=
Solvency0=
Growth32=
Track record94
Bankruptcy probability, 12 months
2.5%
Moderate
0%0.5%1.5%4%10%≥ 25%
No credit on open account
Liquidity ample (current ratio 39.99 against 61.8 in 2024; short-term debt: 0.5% and cash: 17.9% of total assets), but equity is negative.
Credit advice for your own amount and term
Signals
Seven signals. The signal on the left, the evidence on the right.
+raises risk○neutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
-237.3%
Return on assets
-66.3%
Age of the figures
9 mo
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 21
Relative position
BE, all sectors
reference
Sector 21
higher
← fewer bankruptcies
more bankruptcies →
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025Equity per financial year
2122232425
2021 to 2025 · latest year €-352k
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 06-07-2026, 25 days ahead of the deadline.
NBB · 5 filingsDeviation from the deadline
2025
25 d early
2024
9 d early
2023
23 d early
2022
25 d early
2021
27 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
16-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, micro schema
Equity
€-352k▼ 38.8%
2024 · €-254k
2021: €244k
2022: €82k
2023: €-143k
2024: €-254k
2021 → 2025
Total assets
€148k▼ 40.0%
2024 · €248k
2021: €245k
2022: €82k
2023: €209k
2024: €248k
2021 → 2025
Net result
€-98k▲ 11.3%
2024 · €-111k
2021: €-56k
2022: €-163k
2023: €-224k
2024: €-111k
2021 → 2025
Working capital
€27k▼ 68.2%
2024 · €84k
2021: €242k
2022: €80k
2023: €60k
2024: €84k
2021 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€244k-€82k▼ 66.6%€-143k€-254k▼ 77.7%€-352k▼ 38.8%
Operating result€-55k-€-162k▼ 193%€-223k▼ 37.6%€-110k▲ 50.5%€-98k▲ 11.1%
Net result€-56k-€-163k▼ 192%€-224k▼ 37.9%€-111k▲ 50.5%€-98k▲ 11.3%
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result stays negative: a loss of €98k in 2025 against €110k in 2024; the loss shrinks.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €148k
Fixed assets
€121k▼ 25.4%
Current assets
€27k▼ 67.9%
Key figures and ratios
EBITDA
€-56k▲
2024 · €-77k
Cash flow
€-57k▲
2024 · €-77k
Solvency
-237.3%▼
2024 · -102.5%
Current ratio
39.99▼
2024 · 61.80
Quick ratio
39.99▼
2024 · 61.80
Debt / equity
-1.42▲
2024 · -1.98
ROA
-66.3%▼
2024 · -44.8%
Interest coverage
-239.58▼
2024 · -148.89
Debt
€501k▼
2024 · €501k
Debt ≤ 1 year
€686▼
2024 · €1k
Debt > 1 year
€500k=
2024 · €500k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€248k€148k▼
Fixed assets21/28€162k€121k▼
Intangible fixed assets21€162k€120k▼
Tangible fixed assets22/27€547€794▲
Furniture and vehicles24€547€794▲
Current assets29/58€85k€27k▼
Amounts receivable within one year40/41€476€837▲
Other amounts receivable41€476€837▲
Cash at bank and in hand54/58€85k€27k▼
Equity and liabilities
Total equity and liabilities10/49€248k€148k▼
Equity10/15€-254k€-352k▼
Contributions10/11€300k€300k=
Profit (loss) carried forward14€-554k€-652k▼
Amounts payable17/49€501k€501k▼
Amounts payable after more than one year17€500k€500k=
Other amounts payable178/9€500k€500k=
Amounts payable within one year42/48€1k€686▼
Financial debts43€827€87▼
Credit institutions430/8€827€87▼
Trade debts44€554€599▲
Suppliers440/4€554€599▲
Income statement
Code20242025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€34k€42k▲
Other operating charges640/8€505€724▲
Gross operating margin9900€-76k€-56k▲
Operating profit (loss)9901€-110k€-98k▲
Financial income75/76B€0-
Recurring financial income75€0-
Financial charges65/66B€514€235▼
Recurring financial charges65€514€235▼
Profit (loss) for the period before taxes9903€-111k€-98k▲
Profit (loss) for the period9904€-111k€-98k▲
Profit (loss) for the period to be appropriated9905€-111k€-98k▲
Appropriation of the result
Profit (loss) to be appropriated9906€-554k€-652k▼
Profit (loss) brought forward from the previous period14P€-443k€-554k▼
The notes to these accounts (9 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
06-07
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
22-07
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2024
31-12
Financial
Liquidity doublescurrent ratio 61.80
Current ratio from 27.94 to 61.80; short-term debt falls from €2k to €1k.
08-07
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2023
31-12
Financial
Weakest financial yearnet €-224k
Net result drops to €-224k, the lowest in the series; recovery starts the following year.
06-07
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
2022
04-07
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Kapellen · 1 establishment unit since 2021
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Kasteeldreef 382950 KapellenGround area
1.1 ha
Building footprint
383 m²
Volume, LiDAR
2,444 m³
Parcel 11902H0095/00P003, Flanders · tallest building 11.5 m, ±2 floors. Linked by address, not a title deed.
1 establishment unit
Novozymatic
since 20212.314.685.165
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 11902H0095/00P003 | Flanders | 1.1 ha | 1 · 383 m² | 11.5 m · 2 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
SUPERBIOTICS
BE 0719.267.569
Eghezée · Eq €84k
CLARETHIS
BE 0894.880.626
Soignies · Eq €86k
Abella Mar
BE 0740.524.031
Kapellen · Eq €75k
Pharmacie BIHAIN
BE 0562.948.012
Trois-Ponts · Eq €90k
REGEN CONSULTING
BE 0791.163.078
Chaumont-Gistoux · Eq €91k
Of 149 companies in sector 21100 we hold annual accounts for 108. 62 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded19-01-2021
Fiscal year end31-12
Activities, NACEBEL
21100Manufacture of basic pharmaceutical products and pharmaceutical preparations
21201Manufacture of basic pharmaceutical products and pharmaceutical preparations
46460Wholesale of pharmaceutical and medical goods
64200Holdings
64210Activities of holding companies
70200Business and other management consultancy
70220Business consulting
82100Office administrative and support services
82110Office administrative, office support and other business support activities
Sources
Crossroads Bank for EnterprisesNational Bank · 5 filingsAddress and cadastre registers
Data from official sources, last processed on 15-09-2026. Scores and ratios are computed by Checked and are not a credit decision.